Skip to main content

Inlyta FDA Approval History

FDA Approved: Yes (First approved January 27, 2012)
Brand name: Inlyta
Generic name: axitinib
Dosage form: Tablets
Company: Pfizer Inc.
Treatment for: Renal Cell Carcinoma

Inlyta (axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.

Development timeline for Inlyta

DateArticle
May 14, 2019Approval  FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
Apr 22, 2019Approval FDA Approves Keytruda (pembrolizumab) in Combination With Inlyta (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
Jan 27, 2012Approval FDA Approves Inlyta for Advanced Renal Cell Carcinoma
Dec  7, 2011FDA Advisory Committee Finds The Benefit/Risk Profile Of Axitinib In Previously Treated Advanced Renal Cell Carcinoma (RCC) To Be Favorable
Jul  7, 2011Pfizer Files With The FDA For Review Of Axitinib For Patients With Advanced Renal Cell Carcinoma

See also

Inlyta (axitinib) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer